Substitute form 1449A/PTO	OF	Complete if Known		
	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	Application Number	10/008,062	
INFORMATION DISCLOSURE	/0	Filing Date	10/19/2001	
STATEMENT BY APPLICANT	2005	First Named Inventor	David Rizzieri	
STATEMENT BY ATTEMANT	SEP 2 2 2005	Group Art Unit	1642 643	
(use as many sheets as necessary)	1 20	Examiner Name	Alana M. Harris	
Sheet 1 of	1 7	Attorney Docket Number	5405-252	

U.S. PATENTS AND PATENT PUBLICATIONS						
Examiner Cit Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	
		Number	Kind Code (if known)	- Bodinant	MM-DD-YYYY	
		US-				
		US-			<u> </u>	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
-		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-			•	
		US-				
		US-				
		US-				
	1	US-				

FOREIGN PATENT DOCUMENTS							
	Cite		Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of	Translation
	No.	Office	Number	Kind Code (if known)	Document	Cited Document MM-DD-YYYY	
auch	1	wo	92/04464	A2	The Wistar Institute	03/19/1992	
	<u> </u>						
	<u> </u>	-				 	<u> </u>

Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
2	Supplementary Partial European Search Report, EP 01 99 6085, 07/06/2005	
3	Kaminski et al., "Radioimmunotherapy with iodine 131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience", Blood, 96(4):1259-1266 (2000)	
		<u> </u>
	No.	No. serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/cr country where published Supplementary Partial European Search Report, EP 01 99 6085, 07/06/2005 Kaminski et al., "Radioimmunotherapy with iodine 131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan

Examiner Signature	ansil	Aldies	Date Considered	03/	07/200	06